Prevention of NSAID-related ulcers
- Frank L. Lanza MD, FACG
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The use of NSAIDs constitutes a significant risk for gastrointestinal bleeding and other ulcer complications. However, if they prove clinically effective in relieving arthritic symptoms, the new COX-2 selectively inhibiting NSAIDs may ultimately solve the problem of gastrointestinal toxicity with NSAIDs.
- Cryer B, Feldman M: Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal, anti-inflammatory drug-induced damage. Arch Intern Med. 1992;152:1145–1155. CrossRef
- Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987:1153–1158.
- Bellary SV, Isaacs PET, Lee FI. Upper gastrointestinal lesions in elderly patients presenting for endoscopy: relevance of NSAID usage. Am J Gastroenterol. 1991;86:961–964.
- Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241–249.
- Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787–796.
- Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforation and hemorrhage. Br Med J. 1985;290:347–349.
- Collier DSTJ, Pain JA. Nonsteroidal anti-inflammatory drugs and peptic ulcer perforation. Gut. 1985;26:359–363.
- Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use in peptic ulcer disease; role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740.
- Sharr RJ, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Ann Intern Med. 1993;153:1665–1670. CrossRef
- Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769–772. CrossRef
- Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:1075–1078. CrossRef
- Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin anti-inflammatory drugs. Gastroenterology. 1993;105:1078–1088.
- Garcia-Rodriguez LA, Cattaruzzi C, Grazia Troncon M, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other hypertensive drugs. Arch Intern Med. 1998;158:33–39. CrossRef
- Ehsannulah RSB, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J. 1988; 297:1017–1021. CrossRef
- Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34(3): 424–428. CrossRef
- Levin LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993;153:449–454.
- Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med. 1996;334:1435–1439. CrossRef
- Agrawal NM, Rogh SH, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer in randomized control trial. Ann Intern Med. 1991;115:195–200.
- McCarthy DM. Sucralfate. N Engl J Med. 1991;325:1017–1025. CrossRef
- Ekstrom P, Carling L, Wetterhus S, Wingren PE, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal anti-inflammatory drug therapy. Scand J Gastroenterol. 1996;31(8):753–758.
- Hawkey CJ, Karrasch JA, Szczepa L, et al: Omeprazole for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1998;338(11):727–734. CrossRef
- Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1998;338 (11):719–726. CrossRef
- Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind placebo-controlled trial. Lancet. 1988;ii:1277–1280. CrossRef
- Graham DY, White RH, Moreland W, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119(4):257–262.
- Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344–350.
- Elliott SL, Yeomans ND, Buchanan RR, et al. Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol. 1994;23(4):171–176.
- Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91:223–227.
- Naschitz JE, Yeshuran B, Odeh B, et al. Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol. 1990;85:408–411.
- Koch M, Dezi A, Ferrario F, et al. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Arch Intern Med. 1996;156:2331–2322. CrossRef
- Laine L, Marin-Sorenson M, Weinsein WM. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol. 1992;87:1398–1402.
- Herebach B, Raoul JL, Bretagne JF, et al. Helicobacter pylori: a risk of severity factor of nonsteroidal anti-inflammatory drug-induced gastropathy. Gut. 1992;33:1608–1611.
- Kim JG, Graham DY: Helicobacter pylori infection and development of duodenal ulcer in arthritic patients receiving chronic NSAID therapy: the Misoprostol Study Group. Am J Gastroenterol. 1994;89:203–207.
- Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–979. CrossRef
- Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arth Rheum. 1998;41(9):1591–1602. CrossRef
- Lanza FL, Simon T, Bolognese J, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than aspirin or ibuprofen. Aliment Pharmacol Ther. 1999;13(6):761–767. CrossRef
- Prevention of NSAID-related ulcers
Volume 26, Issue 2 , pp 103-108
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Author Affiliations
- 1. Baylor College of Medicine, 2500 Fondren Rd., STE 250, 77068, Houston, TX